Latest News: 20/20 GeneSystems Presents a Technology Update at the BIO 2003 Meeting... 20/20 GeneSystems BioCheckTM product profiled in the Business Gazette....20/20 Launches Innovative Bio-Terrorism Field Test for 1st Responders...... 20/20 Enters Technology Access Agreement with Novartis...... 20/20 Receives $50,000 Award from TEDCO...... 20/20 GeneSystems Receives a Quarter of a Million Dollars in Funding from Agencies Promoting Maryland Biotech...... 20/20 GeneSystems Profiled in The Gazette...... 20/20 GeneSystems Wins TCM Bioscience Product of the Year Award...... Kodak Marketing 20/20 GeneSystems’ Proteomics Product.....         Wako to Distribute 20/20 GeneSystems’ Proteomics Product in the Far East.....Updated Listing of Proteomics Product Customers.....20/20 GeneSystems And Bear Code Partner In         Software Development

20/20 Gene Systems, Inc. (“20/20”) is a biotechnology company that develops and commercializes innovative identification and detection products for proteins, the building blocks of life. The company’s proprietary technology addresses three large and growing markets:

Our primary intellectual property platform—Layered Gene Scanning (LGS) – was exclusively licensed from the National Institutes of Health (NIH) and is being co-developed between 20/20 and several NIH scientists¹. This technology provides drug companies and life scientists with a digital “snapshot” of the proteins in disease samples and is predicted to become the premier technology in diagnostic pathology within four years.

1  Published references

©20/20 GeneSystems, Inc., 2002-2004 Patents Pending